Who are Hyperoncotic Albumin 20%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Albumin administration, Isooncotic Albumin 5%, Hydroxyethylstarch 130/0,4, Human Albumin (colloid), Voluven (HES 130/0.4), Human Albumin 20%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hyperoncotic-albumin-20.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Hyperoncotic Albumin 20% — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hyperoncotic Albumin 20% (Hyperoncotic Albumin 20%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Colloid volume expander. Area: Critical Care / Acute Medicine.

marketed Colloid volume expander Critical Care / Acute Medicine Small molecule Live · refreshed every 30 min

Target snapshot

Hyperoncotic Albumin 20% (Hyperoncotic Albumin 20%) — Insel Gruppe AG, University Hospital Bern. Hyperoncotic albumin 20% increases plasma oncotic pressure to draw fluid from interstitial spaces into the intravascular compartment, expanding blood volume and improving tissue perfusion.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Hyperoncotic Albumin 20% TARGET	Hyperoncotic Albumin 20%	Insel Gruppe AG, University Hospital Bern	marketed	Colloid volume expander
Albumin administration	Albumin administration	Rennes University Hospital	marketed	Colloid volume expander
Isooncotic Albumin 5%	Isooncotic Albumin 5%	Insel Gruppe AG, University Hospital Bern	marketed	Colloid volume expander
Hydroxyethylstarch 130/0,4	Hydroxyethylstarch 130/0,4	Rigshospitalet, Denmark	marketed	Synthetic colloid volume expander
Human Albumin (colloid)	Human Albumin (colloid)	The University of Texas Health Science Center, Houston	marketed	Colloid volume expander
Voluven (HES 130/0.4)	Voluven (HES 130/0.4)	Sangart	phase 3	Colloid volume expander
Human Albumin 20%	Human Albumin 20%	Asian Institute of Gastroenterology, India	phase 3	Colloid volume expander

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Colloid volume expander class)

Insel Gruppe AG, University Hospital Bern · 2 drugs in this class
Asian Institute of Gastroenterology, India · 1 drug in this class
Rennes University Hospital · 1 drug in this class
Sangart · 1 drug in this class
The University of Texas Health Science Center, Houston · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hyperoncotic Albumin 20% — Competitive Intelligence Brief. https://druglandscape.com/ci/hyperoncotic-albumin-20. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab